Private Wealth Partners LLC Has $12.43 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Private Wealth Partners LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 76,274 shares of the company’s stock after selling 686 shares during the period. Zoetis accounts for about 1.0% of Private Wealth Partners LLC’s investment portfolio, making the stock its 27th biggest holding. Private Wealth Partners LLC’s holdings in Zoetis were worth $12,427,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Private Advisor Group LLC raised its stake in shares of Zoetis by 2.3% during the 4th quarter. Private Advisor Group LLC now owns 29,149 shares of the company’s stock worth $4,749,000 after purchasing an additional 654 shares in the last quarter. Bryn Mawr Capital Management LLC increased its holdings in Zoetis by 25.0% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 20,902 shares of the company’s stock worth $3,406,000 after buying an additional 4,178 shares during the last quarter. Alberta Investment Management Corp raised its position in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after acquiring an additional 28,700 shares in the last quarter. Legacy Solutions LLC acquired a new stake in Zoetis in the fourth quarter valued at $209,000. Finally, Bank of Jackson Hole Trust bought a new position in shares of Zoetis in the 4th quarter valued at about $641,000. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler reduced their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $214.90.

Zoetis Trading Up 0.3 %

Shares of Zoetis stock opened at $156.92 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a 50-day moving average of $167.29 and a 200-day moving average of $178.29. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The stock has a market cap of $70.27 billion, a PE ratio of 28.69, a PEG ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.06 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.